1. Advances in Severe Asthma Management

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Pathophysiology of Severe Asthma

5. Asthma and Healthcare Utilization

6. Inflammatory Mechanisms in Severe Asthma Type 2 Inflammation

7. Downstream Mediators Trigger Type 2 Asthma

8. Mast Cells

9. Current Therapeutic Targets

10. Future Targets for Therapies

11. Concluding Remarks

12. Managing Severe Asthma in Patients With Comorbid Type 2 Diseases

13. Asthma-Associated Comorbidities

14. Type 2 Comorbidities and Asthma Exacerbations

15. Allergic Rhinitis Prevalence in Asthma

16. Allergic Rhinitis Clinical Presentation

17. Chronic Rhinosinusitis

18. Nasal Polyps

19. GERD

20. Atopic Dermatitis

21. Biologics for the Treatment of Type 2 Comorbidities

22. Dupilumab Treatment of CRSwNP

23. Dupilumab Treatment of AR

24. Concluding Remarks

25. Use of Biomarkers to Tailor Therapy for Severe Asthma

26. Biomarkers

27. Biomarkers in Asthma

28. Biomarkers in Asthma (Cont.)

29. Eosinophils

30. FeNO

31. Periostin Possible Future Biomarker

32. Concluding Remarks

33. Data on Long-Term Treatment With Targeted Therapies

34. Approved Targeted Therapies Severe Asthma

35. Omalizumab EXTRA Study

36. Mepolizumab SIRIUS Study

37. Benralizumab ZONDA Study

38. Phenotypes and Biomarkers Putting Knowledge Into Practice

39. Patient Considerations for Treatment

40. Emerging Data on Biologic Therapies for Severe Asthma

41. Targets for Investigational Treatments

42. Dupilumab

43. Dupilumab Phase 3: Quest Study

44. QUEST Study Results

45. QUEST Study Results (Cont)

46. VENTURE Study

47. VENTURE Study Results

48. Dupilumab Safety Data

49. TSLP

50. Tezepelumab

51. Fevipiprant

52. Concluding Remarks

53. Abbreviations

54. Abbreviations (cont)

55. Abbreviations (cont)